Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 9,944 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infectious Clear all

Conditions: Substance Abuse, HIV Infections
Interventions: Bupropion, Placebo; Drug
Lead sponsor: San Francisco Department of Public Health; Government
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Stavudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 1999
U.S. locations: 3
States / cities: San Diego, California • Portsmouth, Virginia • Seattle, Washington

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Postherpetic Neuralgia
Interventions: ATx08-001, Placebo; Drug
Lead sponsor: Aestus Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 9
States / cities: Chandler, Arizona • Peoria, Arizona • Cutler Bay (Miami), Florida + 5 more

Conditions: HIV Infections, Hemophilia A
Interventions: Ibuprofen, Zidovudine; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Staphylococcal Infection
Interventions: Trimethoprim-sulfamethoxazole, Placebo, Clindamycin; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 85 Years
Enrollment: 1,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 6
States / cities: San Francisco, California • Torrance, California • Atlanta, Georgia + 3 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Abacavir sulfate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 16 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Surgical Site Infection
Interventions: intranasal povidone-iodine; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: SARS-CoV-2 Infection, Acute Kidney Injury
Interventions: Placebo, Nicotinamide riboside; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: New York, New York • San Antonio, Texas • Seattle, Washington

Conditions: Progressive Multifocal Leukoencephalopathy
Interventions: Brincidofovir; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection
Interventions: PET Tracer, MRI Tracer, 3T PET/MRI; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV, HIV/AIDS, HIV-1 Infection
Interventions: Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074; Drug
Lead sponsor: Luis Montaner; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Thymic Humoral Factor, Zidovudine; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
Interventions: Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 11
States / cities: Long Beach, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: HIV Infections
Interventions: Medication Reminder System/Adherence Tracker; Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: Diabetes, Heart Diseases, Diet Habit, Diet Modification, Healthy, Obesity, Metabolism, Microbial Colonization
Interventions: Dietary Intervention; Other
Lead sponsor: Zoe Global Limited; Other
Eligibility: 18 Years and older
Enrollment: 250,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: Corona Virus Infection
Interventions: anti-SARS-CoV-2 human convalescent plasma; Biological
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 1 Month to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV, AIDS
Interventions: Video or In-Person Presentation; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: HIV Infection
Interventions: atazanavir, lopinavir/ritonavir; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 60 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Hepatitis C Virus, Hiv Infections
Interventions: bavituximab; Drug
Lead sponsor: Peregrine Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 3 more

Conditions: Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections, Abscess
Interventions: Radezolid, Linezolid; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Montgomery, Alabama • Long Beach, California • Los Angeles, California + 16 more

Conditions: Herpes Simplex, HIV Infections
Interventions: Vidarabine, Acyclovir, Foscarnet sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Rochester, New York + 1 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: indinavir (MK-0639); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM

A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.

A Study of Health-Related Quality of Life in HIV-Infected Patients Undergoing Structured Treatment Interruptions of Highly Active Antiretroviral Therapy

Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia

The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia

Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.

Nasal Decolonization for Orthopedic Trauma Patients

Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients

The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

Handheld Computers to Improve Adherence to Anti-HIV Drug Regimens

Personalized Responses to Dietary Composition Trial 3

Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions

Video-Based Delivery of HIV Test Information for Spanish-Speaking Latinos

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir

A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection